FDC Ltd

FDC Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 June 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters improve from expensive to fair, signalling a notable shift in price attractiveness. Despite a recent day decline of 1.7%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more balanced investment proposition compared to its historically stretched multiples and peer group benchmarks.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable financial turnaround in the quarter ended March 2026. After a period of negative trends, the company’s recent quarterly results reveal significant growth in profitability metrics, signalling a positive shift in its financial trajectory despite lingering concerns over non-operating income contributions.

FDC Ltd., a fully integrated pharmaceutical company specialising in formulations and active pharmaceutical ingredients, reported a remarkable turnaround in Q4 FY26 with consolidated net profit surging 167.39% year-on-year to ₹103.40 crores, compared to ₹38.67 crores in Q4 FY25. The quarter-on-quarter performance was even more dramatic, with profits jumping 265.37% from ₹28.30 crores in Q3 FY26. Despite this impressive headline performance, the stock has struggled over the past year, declining 6.95%, whilst the broader pharmaceuticals sector gained 11.45%. The company, with a market capitalisation of ₹6,692 crores, trades at a P/E multiple of 30x, reflecting investor concerns about sustainability of earnings and margin volatility.

The Sensex declined 0.25% on 26 May 2026, while FDC Ltd surged 10.69%, marking a striking 8.66-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, which touched an intraday high of Rs 404, up 9.2% from its previous close.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 May 2026, providing investors with the latest insights into its performance and outlook.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bearish to a mildly bearish trend. Despite a modest 1.05% gain in the latest session, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum tools, prompting a downgrade to a Strong Sell rating by MarketsMOJO as of 3 Nov 2025.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Despite a broadly recovering market, FDC Ltd has slipped to a fresh 52-week low of Rs 314.75 on 30 Mar 2026, marking a continuation of its recent downward trajectory with a 3-day losing streak and a 3.8% decline over this period.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 29 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

While the broader market has shown signs of recovery, FDC Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 318.1 on 27 Mar 2026. This decline comes amid a backdrop of underwhelming financial performance and waning institutional support, raising questions about the stock’s near-term outlook.

FDC Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.323.2 on 24 March 2026, marking a significant decline in its stock price amid a sustained downward trend over recent sessions.

FDC Ltd’s share price declined to a fresh 52-week low of Rs.325.9 on 23 March 2026, marking a significant downturn for the pharmaceutical company amid subdued financial results and broader market weakness. The stock’s recent performance reflects ongoing challenges in growth and profitability, compounded by a cautious market environment.